Knowledge HQ

This study describes a BiTE derived from a TCR-mimic antibody against WT1. It induced T-cell cytotoxicity against WT1+ tumors and epitope spreading. Transduced EBV-specific T lymphocytes used in in vivo tracking studies were cultured in G-Rex®.

The authors developed Go-CART, a six-chambered device to assess CAR T cell function without animals. The device features a gas-permeable base, allowing prolonged T cell-tumor interaction (>2 weeks) without medium replenishment, similar to G-Rex® technology (co-author John Wilson is from Wilson Wolf).

This study demonstrates that the immune system can mount a mutation-specific Th1 response against epithelial cancer. Adoptive transfer of enriched mutation-specific CD4+ TILs led to tumor regression. The provided excerpts do not explicitly mention the use of G-Rex® devices.

This study generated CD19-specific CAR T cells using the piggyBac transposon system and expanded them in G-Rex® 10 devices under serum-free conditions. This protocol produced clinically relevant numbers of CAR T cells that were effective against TKI-resistant Ph+ ALL cells.

This study demonstrates that CAR-redirected EBV-CTLs engineered to express IL-7Ra can be selectively expanded by IL-7 in the presence of Tregs. G-Rex® were used to generate the expanded Tregs used in the suppression assays. This strategy enhances antitumor activity.

This abstract reports the clinical use of rapidly generated pentavalent virus-specific T cells expanded in G-Rex® devices. The single-stimulation G-Rex® protocol produced sufficient cells in 10 days to safely and effectively treat drug-refractory EBV, CMV, Adv, BK, and HHV6 infections in HSCT patients.

This study compared fresh activated NK cells vs. ex vivo expanded NK cells (Ex-NK) produced in G-Rex® devices. Ex-NK cells showed distinct homing to bone marrow and higher cytokine dependence (IL-15) compared to fresh cells. The study highlights how manufacturing methods influence in vivo behavior.

This study developed a protocol for generating canine CAR T cells targeting HER2. G-Rex® culture devices were used to expand the activated canine T cells, achieving approximately 100-fold expansion in 8 days. The cells demonstrated antigen-specific cytotoxicity against canine osteosarcoma.

This study engineered EBV-specific T cells with a chimeric IL4/7 receptor to convert inhibitory IL4 signals into stimulatory IL7 signals. G-Rex® were utilized to maintain the EBV-LCL feeder cells used for T cell stimulation. The modified cells showed enhanced antitumor activity in IL4-rich environments.

This review discusses methods for clinical-grade NK cell expansion. It highlights the optimization of NK cell expansion in G-Rex® using K562-mbIL15-41BBL feeder cells, achieving high yields (up to 5x10^8 cells per G-Rex®100) with reduced handling compared to bags.

This study evaluates shipping human islets in high density using silicone rubber membrane (SRM) vessels (G-Rex®). The method maintained islet viability and function comparable to low-density controls, allowing an entire clinical islet isolation to be shipped in a single vessel.

This dissertation analyzes human Treg subsets and their TCR repertoires. It demonstrates that expanding Tregs in G-Rex®10 devices with rapamycin enhances expansion (at least 50-fold) compared to plates, while maintaining FoxP3 expression and suppressive function, facilitating clinical translation.